Neovacs - strong bullish trend expected

8 de fev. de 2019

Results of IFN Kinoide on Lupus research are very significant (95% efficacy observed). Volume increase strongly on the biotech and strong breakout of the 0.25 resistance has been observed. Pullback on the 0.25 level is resolved and the stock is now in perfect conditions for a bullish rally. First target is 0.5